HOME >> BIOLOGY >> NEWS
Faster coagulation rates found in natural systems could impact industrial processing

Using new ways to analyze and describe the rate at which minute ocean-going groups of bacteria or plankton coagulate, a Penn State engineer has found that large aggregates of these groups collide with and capture additional particles millions of times faster than predicted by existing theories.

Dr. Bruce E. Logan, the Kappe professor of environmental engineering, says, "Our results have caused us and many other scientists and engineers to think completely differently about how biological aggregates form in aqueous systems. Such coagulation processes are important in wastewater treatment and industrial manufacturing as well as the ocean and other natural water systems."

Logan is the first to apply the use of fractal geometry to aqueous biological aggregates. Objects arranged in fractal patterns, a snowflake, for example, often look "lacy" and every unit or fragment of it looks like the whole.

Previous methods for describing and predicting the dimensions of biological aggregates have been based on the analysis of single "ideal" particles such as a sphere. However, Logan points out that most real aggregates of interest form particles that have a variety of sizes and shapes. In order to analyze average properties of real aggregates, Logan and his research group have developed new techniques to estimate fractal dimensions and calculate the collision efficiencies between the fractal aggregate and new adhering particles.

Logan will describe the new techniques and calculations at the national meeting of the American Chemical Society in Washington, D. C. on Sunday, August 20. His keynote lecture is entitled, "Fractal Coagulation Processes.

In his experiments, Logan added fluorescent beads to water already containing bacterial aggregates. The coagulation rate, or the rate at which the beads attached to the bacterial aggregates, was calculated by using a microscope to observe and count them over time. He and his research associat
'"/>

Contact: Barbara Hale
bah@psu.edu
814-865-9481
Penn State
19-Aug-2000


Page: 1 2

Related biology news :

1. Faster carbon turnover in basal food-chain levels in aquatic than terrestrial ecosystems
2. Faster method for growing adult stem cells for bone regeneration developed at Hebrew University
3. Faster nanowires may advance nanotechnological applications for detecting glucose, hormones or DNA
4. Dismantling Dangerous Genetic Codes With A Faster, More Flexible RNA Mimic
5. Scientists Invent Faster Gene Function Identification System
6. Core Spins Faster Than Earth, Scientists Find
7. Intake Of Acetaminophen Increases Risk Of Excessive Anticoagulation In Patients Taking Warfarin
8. ICTP celebrates 40th anniversary, Legacy for the Future
9. New genetic research demonstrates possible cause of inherited form of Parkinsons disease
10. UNC research accelerates discovery of novel gene function
11. Land Regeneration Network celebrates first year success

Post Your Comments:
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: